Edesa Biotech Stock Price Soared. Will It Continue to Rise?

Edesa Biotech Filed an IND for EB05
Edesa Biotech (EDSA), a clinical-stage biopharmaceutical company, has filed an investigational new drug (IND) application with the U.S. FDA for the initiation of a Phase 2/3 clinical study of its investigational drug EB05. Edesa has recently received expedited approval to begin the Phase 2/3 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.